Gilead Sciences discovers, develops, and delivers innovative therapeutics for serious viral, oncologic, and inflammatory diseases, maintaining a portfolio of over 25 approved medicines and a pipeline of 47 clinical‑stage programs. The company expands global access through licensing, partnerships, and philanthropy, reaching patients in more than 120 countries while integrating ESG initiatives to support sustainable health outcomes.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with life‑threatening viral, cancerous, and inflammatory diseases often lack effective, affordable therapies, and many existing treatments are unavailable in low‑resource settings, leading to high morbidity and mortality worldwide.
Solution
Gilead Sciences focuses on discovering, developing, and delivering innovative therapeutics for serious diseases in the areas of virology, oncology, and inflammation. The company maintains a portfolio of more than 25 approved medicines and a robust pipeline of clinical‑stage programs aimed at expanding treatment options. Through global licensing, partnership agreements, and local collaborations, Gilead works to increase access to its therapies in over 120 countries, especially in resource‑limited regions. Its research investment of $5.7 billion (2025) supports rapid progression of candidates from early discovery to late‑stage trials. The organization also integrates ESG initiatives—such as renewable energy use, water neutrality goals, and corporate philanthropy—to ensure that the delivery of medicines does not compromise environmental or social sustainability. By combining scientific innovation with structured access programs, Gilead seeks to improve health outcomes for individual patients and entire communities.
Target Audience
Primary customers include patients with life‑threatening viral, oncologic, or inflammatory conditions, healthcare providers and health systems seeking advanced therapies, and public‑sector or nonprofit partners focused on expanding access in low‑resource settings.
Features
- Portfolio of 25+ globally marketed medicines addressing HIV, viral hepatitis, cancer, and inflammatory diseases
- Diverse pipeline with 47 clinical‑stage programs across virology, oncology, and inflammation, including multiple Phase 1‑3 candidates
- Extensive access strategy: voluntary licensing in 120+ countries, partnerships delivering 21.6 M HIV/HBV treatments in 2025, and $260 M+ corporate philanthropy
- Integrated ESG framework targeting 100 % renewable energy in operations, water neutrality by 2030, and net‑zero emissions goals
- Collaborative model that leverages external partnerships, licensing rights, and opt‑in programs to accelerate development and commercialization
- Commitment to community health equity through programs that support testing, treatment adherence, and health system strengthening in underserved regions